• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Immatics N.V.

    8/13/24 7:07:01 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    6-K
    false2024-06-302024Q20001809196--12-31“Short-term deposits” are classified within the balance sheet item “Other financial assets”. Other current/non-current assets comprise mainly of accrued interest and deposits. 0001809196 2024-06-30 0001809196 2023-12-31 0001809196 2024-04-01 2024-06-30 0001809196 2023-04-01 2023-06-30 0001809196 2024-01-01 2024-06-30 0001809196 2023-01-01 2023-06-30 0001809196 2023-06-30 0001809196 2022-12-31 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001809196 imtx:BmsAndModernaCollaborationAgreementMember 2024-04-01 2024-06-30 0001809196 imtx:BMSCollaborationAgreementMember country:US 2024-04-01 2024-06-30 0001809196 imtx:ModernaCollaborationAgreementMember country:US 2024-04-01 2024-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2024-04-01 2024-06-30 0001809196 srt:BoardOfDirectorsChairmanMember 2024-04-01 2024-06-30 0001809196 imtx:RentalLandMember 2024-04-01 2024-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember country:US 2023-04-01 2023-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2023-04-01 2023-06-30 0001809196 imtx:ModernaCollaborationAgreementMember country:US 2023-04-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember 2023-04-01 2023-06-30 0001809196 ifrs-full:OtherReservesMember 2024-01-01 2024-06-30 0001809196 ifrs-full:RetainedEarningsMember 2024-01-01 2024-06-30 0001809196 ifrs-full:SharePremiumMember 2024-01-01 2024-06-30 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2024-01-01 2024-06-30 0001809196 imtx:NonInterestBearingLiabilityMember 2024-01-01 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2024-01-01 2024-06-30 0001809196 imtx:MatchingStockOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:ConvertedOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember imtx:GrantedOnJuneTwoThousandAndTwentyFourMember 2024-01-01 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember imtx:GrantedOnJuneTwoThousandAndTwentyFourMember 2024-01-01 2024-06-30 0001809196 imtx:ConvertedOptionsMember imtx:GrantedOnJuneTwoThousandAndTwentyMember 2024-01-01 2024-06-30 0001809196 imtx:ShareReinvestmentMember imtx:ModificationOfTwoThousandAndSixteenPlanMember 2024-01-01 2024-06-30 0001809196 imtx:ShareReinvestmentMember imtx:ModificationOfTwoThousandAndSixteenPlanMember imtx:MatchingStockOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:MatchingStockOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:ShareReinvestmentMember imtx:ModificationOfAwardsUnderTwoThousandTenAndTwoThousandAndSixteenPlanMember imtx:MatchingStockOptionsMember 2024-01-01 2024-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001809196 ifrs-full:IssuedCapitalMember 2024-01-01 2024-06-30 0001809196 imtx:GenmabCollaborationAgreementMember 2024-01-01 2024-06-30 0001809196 ifrs-full:OrdinarySharesMember ifrs-full:IssuedCapitalMember 2024-01-01 2024-06-30 0001809196 ifrs-full:OrdinarySharesMember ifrs-full:SharePremiumMember 2024-01-01 2024-06-30 0001809196 imtx:ImmaticsBiotechnologiesGmbhMember country:DE 2024-01-01 2024-06-30 0001809196 imtx:BMSCollaborationAgreementMember country:US 2024-01-01 2024-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2024-01-01 2024-06-30 0001809196 imtx:ModernaCollaborationAgreementMember country:US 2024-01-01 2024-06-30 0001809196 srt:BoardOfDirectorsChairmanMember 2024-01-01 2024-06-30 0001809196 imtx:OfficeEquipmentAndInstallationsMember 2024-01-01 2024-06-30 0001809196 ifrs-full:OtherReservesMember 2023-01-01 2023-06-30 0001809196 ifrs-full:RetainedEarningsMember 2023-01-01 2023-06-30 0001809196 ifrs-full:SharePremiumMember 2023-01-01 2023-06-30 0001809196 imtx:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001809196 imtx:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001809196 ifrs-full:IssuedCapitalMember 2023-01-01 2023-06-30 0001809196 imtx:GenmabCollaborationAgreementMember country:DK 2023-01-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember country:US 2023-01-01 2023-06-30 0001809196 imtx:ModernaCollaborationAgreementMember country:US 2023-01-01 2023-06-30 0001809196 imtx:BMSCollaborationAgreementMember 2023-01-01 2023-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2024-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:OtherCurrentNonCurrentAssetsMember 2024-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:TradeReceivablesMember 2024-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:ShorttermDepositsMember 2024-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:CashAndCashEquivalentsMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember ifrs-full:LeaseLiabilitiesMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember imtx:LiabilitiesForWarrantsMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember imtx:OtherCurrentLiabilitiesMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember imtx:AccountsPayablesMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2024-06-30 0001809196 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2024-06-30 0001809196 ifrs-full:AtCostOrInAccordanceWithIFRS16WithinFairValueModelMember 2024-06-30 0001809196 ifrs-full:LeaseLiabilitiesMember ifrs-full:AtCostOrInAccordanceWithIFRS16WithinFairValueModelMember 2024-06-30 0001809196 imtx:ReorganizationMember 2024-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2024-06-30 0001809196 imtx:ConvertedOptionsMember 2024-06-30 0001809196 imtx:MatchingStockOptionsMember 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember imtx:TrancheTwoMember 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember imtx:TrancheThreeMember 2024-06-30 0001809196 imtx:PerformanceBasedOptionsMember imtx:TrancheOneMember 2024-06-30 0001809196 imtx:CashAndCashEquivalentsMember 2024-06-30 0001809196 imtx:LiabilitiesForWarrantsMember 2024-06-30 0001809196 imtx:OtherCurrentLiabilitiesMember 2024-06-30 0001809196 imtx:AccountsPayablesMember 2024-06-30 0001809196 imtx:OtherCurrentNonCurrentAssetsMember 2024-06-30 0001809196 ifrs-full:TradeReceivablesMember 2024-06-30 0001809196 imtx:ShorttermDepositsMember 2024-06-30 0001809196 ifrs-full:LeaseLiabilitiesMember 2024-06-30 0001809196 ifrs-full:TopOfRangeMember 2024-06-30 0001809196 imtx:CollaborationAgreementMember 2024-06-30 0001809196 ifrs-full:OtherAssetsMember 2024-06-30 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2024-06-30 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:CashAndCashEquivalentsMember 2023-12-31 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:ShorttermDepositsMember 2023-12-31 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2023-12-31 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember imtx:OtherCurrentNonCurrentAssetsMember 2023-12-31 0001809196 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:TradeReceivablesMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember ifrs-full:LeaseLiabilitiesMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember imtx:LiabilitiesForWarrantsMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember imtx:OtherCurrentLiabilitiesMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember imtx:AccountsPayablesMember 2023-12-31 0001809196 ifrs-full:AtCostOrInAccordanceWithIFRS16WithinFairValueModelMember 2023-12-31 0001809196 ifrs-full:LeaseLiabilitiesMember ifrs-full:AtCostOrInAccordanceWithIFRS16WithinFairValueModelMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2023-12-31 0001809196 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2023-12-31 0001809196 imtx:ReorganizationMember 2023-12-31 0001809196 imtx:ShorttermDepositsMember 2023-12-31 0001809196 ifrs-full:LeaseLiabilitiesMember 2023-12-31 0001809196 imtx:LiabilitiesForWarrantsMember 2023-12-31 0001809196 imtx:OtherCurrentLiabilitiesMember 2023-12-31 0001809196 imtx:AccountsPayablesMember 2023-12-31 0001809196 imtx:OtherCurrentNonCurrentAssetsMember 2023-12-31 0001809196 ifrs-full:TradeReceivablesMember 2023-12-31 0001809196 imtx:CashAndCashEquivalentsMember 2023-12-31 0001809196 ifrs-full:BottomOfRangeMember 2023-12-31 0001809196 ifrs-full:OtherAssetsMember 2023-12-31 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2023-12-31 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2024-02-07 2024-02-07 0001809196 imtx:PerformanceBasedOptionsMember 2024-02-07 2024-02-07 0001809196 imtx:PerformanceBasedOptionsMember imtx:GrantedOnSeptemberTwoThousandAndTwentyOneMember 2024-02-07 2024-02-07 0001809196 imtx:CelgeneSwitzerlandLlcAndGenmabAsMember 2023-01-01 2023-12-31 0001809196 imtx:RegisteredDirectOfferingMember 2024-01-22 0001809196 ifrs-full:MajorOrdinaryShareTransactionsMember imtx:PublicOfferingMember 2024-01-22 0001809196 imtx:RegisteredDirectOfferingMember 2024-01-22 2024-01-22 0001809196 ifrs-full:IssuedCapitalMember imtx:RegisteredDirectOfferingMember 2024-01-22 2024-01-22 0001809196 ifrs-full:SharePremiumMember imtx:RegisteredDirectOfferingMember 2024-01-22 2024-01-22 0001809196 ifrs-full:MajorOrdinaryShareTransactionsMember imtx:PublicOfferingMember 2024-01-22 2024-01-22 0001809196 imtx:PublicOfferingMember 2024-01-22 2024-01-22 0001809196 ifrs-full:SharePremiumMember imtx:PublicOfferingMember 2024-01-22 2024-01-22 0001809196 ifrs-full:IssuedCapitalMember imtx:PublicOfferingMember 2024-01-22 2024-01-22 0001809196 imtx:AuthorizationOfFinancialStatementsMember 2024-08-13 2024-08-13 0001809196 imtx:GenmabCollaborationAgreementMember 2024-01-01 2024-03-31 0001809196 ifrs-full:BottomOfRangeMember 2024-03-31 0001809196 ifrs-full:BottomOfRangeMember 2023-03-31 0001809196 ifrs-full:TopOfRangeMember 2023-06-30 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2024-03-06 2024-03-06 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2024-06-25 2024-06-25 0001809196 imtx:ShareReinvestmentMember imtx:ModificationOfTwoThousandAndSixteenPlanMember 2020-07-01 2020-07-01 0001809196 imtx:ShareReinvestmentMember imtx:ModificationOfTwoThousandAndSixteenPlanMember 2020-07-01 0001809196 ifrs-full:BottomOfRangeMember 2022-12-31 0001809196 ifrs-full:IssuedCapitalMember 2023-12-31 0001809196 ifrs-full:OtherReservesMember 2023-12-31 0001809196 ifrs-full:RetainedEarningsMember 2023-12-31 0001809196 ifrs-full:SharePremiumMember 2023-12-31 0001809196 imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember 2023-12-31 0001809196 imtx:ConvertedOptionsMember 2023-12-31 0001809196 imtx:MatchingStockOptionsMember 2023-12-31 0001809196 imtx:PerformanceBasedOptionsMember 2023-12-31 0001809196 ifrs-full:IssuedCapitalMember 2024-06-30 0001809196 ifrs-full:SharePremiumMember 2024-06-30 0001809196 ifrs-full:RetainedEarningsMember 2024-06-30 0001809196 ifrs-full:OtherReservesMember 2024-06-30 0001809196 ifrs-full:IssuedCapitalMember 2022-12-31 0001809196 ifrs-full:SharePremiumMember 2022-12-31 0001809196 ifrs-full:RetainedEarningsMember 2022-12-31 0001809196 ifrs-full:OtherReservesMember 2022-12-31 0001809196 ifrs-full:IssuedCapitalMember 2023-06-30 0001809196 ifrs-full:SharePremiumMember 2023-06-30 0001809196 ifrs-full:RetainedEarningsMember 2023-06-30 0001809196 ifrs-full:OtherReservesMember 2023-06-30 iso4217:EUR iso4217:USD xbrli:shares xbrli:pure utr:Year iso4217:EUR xbrli:shares iso4217:USD xbrli:shares utr:Y
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM
    6-K
     
     
    REPORT OF FOREIGN PRIVATE ISSUER
    Pursuant to Rule
    13a-16
    or
    15d-16
    of the Securities Exchange Act of 1934
    August 13, 2024
    Commission File Number:
    001-39363
     
     
    IMMATICS N.V.
     
     
    Paul-Ehrlich-Straße 15
    72076 Tübingen, Federal Republic of Germany
    (Address of Principal Executive Office)
     
     
    Indicate by check mark whether the registrant files or will file annual reports under cover Form
    20-F
    or Form
    40-F.
    Form
    20-F ☒    Form
    40-F ☐
     
     
     

    INFORMATION CONTAINED IN THIS REPORT ON FORM
    6-K
    On August 13, 2024, Immatics N.V. (the “Company”) issued an interim report for the three- and
    six-month
    periods ended June 30, 2024, which is attached hereto as Exhibit 99.1, and issued a press release announcing the second quarter 2024 financial results for the Company, which is attached hereto as Exhibit 99.2.
    INCORPORATION BY REFERENCE
    This Report on Form
    6-K
    (other than Exhibit 99.2
    )
    including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the registration statements on Form
    S-8
    (Registration Nos.
    333-249408,
    333-265820
    and
    333-280935)
    and the registration statements on Form
    F-3
    (Registration Nos.
    333-240260
    and
    333-274218)
    of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
    EXHIBITS
     
    Exhibit Number
      
    Description
    99.1
      
    Immatics N.V. interim report for the three- and six-month periods ended June 30, 2024.
    99.2
      
    Press release dated August 13, 2024.
    101.INS
      
    XBRL Taxonomy Extension Instance Document
    101.SCH
      
    XBRL Taxonomy Extension Schema Document
    101.CAL
      
    XBRL Taxonomy Extension Calculation Linkbase Document
    101.DEF
      
    XBRL Taxonomy Extension Definition Linkbase Document
    101.LAB
      
    XBRL Taxonomy Extension Label Linkbase Document
    101.PRE
      
    XBRL Taxonomy Extension Presentation Linkbase Document
    104    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
     
    1

    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this
    report
    to be signed on its behalf by the undersigned, thereunto duly authorized.
     
       
    IMMATICS N.V.
    Date: August 13, 2024     by:  
    /s/ Harpreet Singh
          Harpreet Singh
          Chief Executive Officer
     
    2

    Get the next $IMTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    9/18/2025$16.00Buy
    Guggenheim
    5/28/2025$10.00Buy
    Deutsche Bank
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    7/15/2021$26.00 → $27.00Outperform
    SVB Leerink
    More analyst ratings

    $IMTX
    SEC Filings

    View All

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    1/12/26 4:09:23 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    12/11/25 7:10:17 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    12/8/25 4:20:54 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Immatics N.V. with a new price target

    Guggenheim initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $16.00

    9/18/25 8:43:36 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Deutsche Bank initiated coverage on Immatics N.V. with a new price target

    Deutsche Bank initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $10.00

    5/28/25 9:08:28 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Immatics N.V. with a new price target

    Piper Sandler initiated coverage of Immatics N.V. with a rating of Overweight and set a new price target of $19.00

    10/7/24 7:57:11 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

    IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor activity in advanced solid tumors after one-time infusion of IMA203CD8 at a low median dose during ongoing dose escalation, including deep and durable responses Promising dose-dependent clinical signal in ovarian carcinoma supports the strategy to position IMA203CD8 in the tumor-agnostic setting of advanced PRAME cancers beyond melanoma, starting with gynecologic cancersDose escalation and determination of RP2D on track to be completed in 2026, including data on two highest dose levels Houston, T

    12/11/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Announces $125 Million Underwritten Offering

    Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125 million. The offering is expected to close on December 8, 2025, subject to customary closing conditions.   Jefferies, Leerink Partners and Cantor are acting as joint book-running managers for the offering. A registration statement rela

    12/5/25 6:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Announces Third Quarter 2025 Financial Results and Business Update

    Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months and mOS not reached at 14.3 months mFUIMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial ongoing with next data update, including dose escalation data in ovarian cancer

    11/17/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Leadership Updates

    Live Leadership Updates

    View All

    Immatics Announces Third Quarter 2025 Financial Results and Business Update

    Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months and mOS not reached at 14.3 months mFUIMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial ongoing with next data update, including dose escalation data in ovarian cancer

    11/17/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Appoints Amie Krause as Chief People Officer

    Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer ("CPO") effective October 27, 2025. Ms. Krause brings more than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business strategy, including across global biopharmaceutical companies. In this newly established role, she will lead Immatics' human resources, focusing on organizational development and operations as the company transitions to commercial stage."As we

    10/27/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Appoints Venkat Ramanan as Chief Financial Officer

    Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer ("CFO"), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos The

    10/1/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Immatics N.V.

    SC 13G - Immatics N.V. (0001809196) (Subject)

    11/14/24 1:28:33 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Immatics N.V.

    SC 13G - Immatics N.V. (0001809196) (Subject)

    11/14/24 6:32:45 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immatics N.V.

    SC 13G/A - Immatics N.V. (0001809196) (Subject)

    11/8/24 10:46:38 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Financials

    Live finance-specific insights

    View All

    Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

    Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors IMA402 PRAME Bispecific at RP2D range resulted in a 30% cORR (6/20) across all indications, including 29% (4/14) in melanoma and 2/3 confirmed responses in ovarian carcinoma IMA401 MAGEA4/8 Bispecific at ≥1 mg resulted in a 25% cORR (2/8) in head and neck cancer, 29% cORR (2/7) in melanoma and promising clinical activity in sqNSCLC Phase 1a dose escalation completed for both trials; data support IMA402 PRAME Bispecific dev

    11/12/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

    Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 trial Regulatory pathway and clinical trial design for IMA203 finalized following FDA Type D meetings and meeting with the Paul Ehrlich Institute (PEI); RP2D and CMC package confirmedIMA203 conti

    10/10/24 6:30:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

    Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research today, November 8 IMA203 GEN1 TCR cell therapy targeting PRAME – update on Phase 1a and Cohort A Continues to be well tolerated50% confirmed objective response rate (cORR) in melanoma patients treated at recommended Phase 2 dose; durability with some ongoing responses at >15 months and median duration of response not reached at a median follow-up of 14.4 monthsTargeted to enter registration-enabling Phase 2 trial in melanoma in 2024; discussions with FDA ongoing based on recently ob

    11/8/23 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care